CASE REPORT

Repetitive transcranial magnetic stimulation (rTMS) as a treatment for chronic dizziness following mild traumatic brain injury

Eric Paxman,¹ Joan Stilling,¹ Leah Mercier,¹ Chantel T Debert^{1,2}

SUMMARY

¹Department of Clinical Neurosciences, Division of Physical Medicine and Rehabilitation, University of Calgary, Calgary, Alberta, Canada ²Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada

Correspondence to

Dr Chantel T Debert, chantel.debert@ahs.ca

Accepted 23 October 2018



© BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Paxman E, Stilling J, Mercier L, *et al. BMJ Case Rep* Published Online First: [*please include* Day Month Year]. doi:10.1136/bcr-2018-226698

A 61-year-old man sustained a mild traumatic brain iniury (mTBI) following a pedestrian versus vehicle traffic accident. Post injury, he began to experience symptoms including light-headedness, spatial disorientation, nausea, fatigue and prominent dizziness brought on by postural change, physical activity or eve movements. Symptoms of dizziness persisted for over 5 years, despite numerous extensive and rigorous vestibular and vision therapy regimens. All investigations suggested normal peripheral and central vestibular functioning. The patient underwent 10 sessions of repetitive transcranial magnetic stimulation (rTMS) treatment, with stimulation of the left dorsolateral prefrontal cortex at 70% of resting motor threshold and a frequency of 10 Hz. Dizziness symptom severity and frequency were reduced by greater than 50% at 3 months post treatment, with a clinically significant reduction of dizziness disability from 40 to 21 points on the Dizziness Handicap Inventory. We propose rTMS as a safe, effective and cost-effective treatment option for patients who experience persistent post-traumatic dizziness secondary to mTBI.

BACKGROUND

It is currently estimated that up to 300 per 100 000 people seek medical attention for mild traumatic brain injury (mTBI) annually, worldwide.^{1 2} Since many people with mTBI may not seek medical attention,³ the true global population incidence is thought to be 45 million people annually, with most cases resulting from falls, sports and motor vehicle accidents.² It is estimated that 85%–90% of all mTBIs will have symptoms resolve within 1 month.⁴ However, up to 10%–25% of patients with mTBI may develop persistent postconcussive symptoms (PPCS),^{5 6} which can continue beyond 1 year post injury in more than 2% of patients.^{5 7}

Ongoing vertigo, dizziness, imbalance and vision changes are common symptoms in the majority of patients following mTBI and are often associated with vestibular system impairments.^{8 9} Up to 81% of these patients will have dizziness on initial examination,¹⁰ which has been shown to prolong recovery when compared with other initial symptoms.¹¹ The aetiology of persistent post-traumatic dizziness may be peripheral or central in origin, affecting inner ear or central nervous system integration and output, respectively. Peripheral vestibular system may also affect eye movement through the vestibulo-ocular reflex (VOR). Thus, vestibular dysfunction can presents as balance impairments, dizziness, vertigo or VOR malfunctioning.⁸ The most common cause of dizziness in patients with PPCS is benign paroxysmal positional vertigo,¹² which is commonly associated with dislodged otoconia in the posterior semicircular canal,⁸ but other aetiologies such as VOR dysfunction, cervicogenic dizziness and post-traumatic vision syndrome may also occur.¹³

Treatment of post-traumatic dizziness in patients with PPCS can be difficult. Vestibular therapy, and to a lesser extent, vision therapy, have been shown to be of some value, but are not always successful. Further, medication and environmental modifications may mitigate symptoms but do not treat the cause. We currently lack a recommended and efficacious treatment for chronic dizziness in PPCS when symptoms persist beyond conventional therapies. This case highlights the use of repetitive transcranial magnetic stimulation (rTMS) as a novel treatment option for patients who suffer from PPCS and chronic dizziness secondary to mTBI.

CASE PRESENTATION

An otherwise healthy 61-year-old right-hand dominant man was struck by a vehicle in a crosswalk, causing him to be thrown a short distance before landing on his back and striking his head on pavement. He had a brief loss of consciousness and on waking, he experienced a transient paralysis of the extremities, lasting a few seconds. The patient was alert and oriented to person, place, time and situation, with a Glasgow Coma Scale of 15 when emergency medical services arrived. He was taken by ambulance in C-spine precautions to the local trauma centre where he had a chest ultrasound and was subsequently discharged home. The patient reported neck soreness, head pain (posterior) and left temporomandibular joint tenderness on the day of the injury. He required stitches in the posterior aspect of the head.

Initial symptoms in the days following the injury included dizziness (in which he described the world spinning), light-headedness, spatial disorientation, nausea and fatigue. These symptoms waxed and waned over time, but persisted and were present 5 years post injury despite seeing many specialists and engaging in a variety of interventions. In the mornings, on awakening, the patient tended to be symptom free. However, dizziness would worsen with any physical activity, prolonged mental activity, postural changes, converging eye movements and changes in depth and colour contrast. Symptoms improved with rest and immobility.

The patient had no family history of neurological conditions. He was on no medications at the time of the incident, with the exception of a daily multivitamin, vitamin C and vitamin D supplements. Venlafaxine (75 mg one time a day) was started 2 years post injury, which helped with mood but did not help with dizziness.

INVESTIGATIONS

The patient was seen by multiple specialists, including neurology, ear/nose/throat, physiatry, sports medicine, dentistry (for a temporomandibular joint night splint), orthopaedic surgery, neuropsychology and psychiatry. A diagnosis of post-traumatic dizziness of idiopathic origin was made. Imaging of the brain (MRI and MR angiogram) and cervical spine (MRI) was completed. There was no evidence of any significant vascular narrowing with the exception of possible minimal atherosclerotic changes at the left common carotid origin; otherwise, no vascular or post-traumatic pathology was identified. In particular, the vertebrobasilar system was patent throughout. There was no evidence of intracranial traumatic lesion or shear microhaemorrhage.

Further testing included neuropsychological assessment, vestibular evoked myogenic potential, computerised dynamic posturography and videonystagmography, which were all normal. A full physical examination was completed, which included postural heart rate and blood pressure, pulse oximetry, cardiology and respiratory examination, and a complete neurological examination, including cerebellar, cranial nerve, motor, sensory, reflexes, tone, frontal lobe release signs, Dix-Hallpike manoeuvre and vision assessment (visual acuity, eye tracking, visual fields and convergence). Only a mild length-dependent sensory polyneuropathy involving the distal 1/3 of the feet was found, which he stated was there prior to the injury. All blood tests, including complete blood count, electrolytes, fasting glucose, serum protein electrophoresis, vitamin B₁₂, thyroid stimulating hormonr, free thyroxine-4, morning cortisol, testosterone, insulin-like growth factor-1, vitamin D and inflammatory markers were within normal limits. A heavy metal screen found all trace elements to be within normal ranges.

The patient participated in extensive rehabilitation. A combination of vestibular therapy and physiotherapy of the cervical spine (including range of motion exercises, intermuscular stimulation, acupuncture, strengthening exercises and manual therapy) was unsuccessful and exacerbated symptoms. Extensive 15-week rehabilitative vision therapy with an optometrist was also unsuccessful. Binasal occlusion therapy (3 weeks) was tried with no benefit. Six months of craniosacral therapy was also completed with little to no benefit. Activator walking poles slightly improved stability and balance but did not reduce symptoms. The cost incurred for the aforementioned therapies was substantial, totalling approximately \$C9550. This estimate included a vision therapy programme (\$C5000), 11 physiotherapy sessions (\$C1320), 25 craniosacral treatments (\$C2345), 8 vestibular therapy sessions and several therapeutic massage treatments.

TREATMENT

The patient underwent 2 weeks of rTMS treatment (10 sessions), which was chosen based on the typical duration for chronic medication refractory depression and medication refractory

migraine protocols.^{14–18} Each session took approximately 45 min to complete and cost approximately \$C300 based on current requirements for usage of the machine and labour. Brainsight TMS neuronavigation software (Rogue Research, Quebec, Canada) with the MRI of the patient was used for the localisation of the TMS stimulation site. The left dorsolateral prefrontal cortex (DLPFC) received rTMS stimulation at an intensity of 70% of resting motor threshold (RMT), with a frequency of 10 Hz. Ten trains of 60 pulses/train (total of 600 pulses) were administered at each session, with an intertrain interval of 45 s. RMT was identified using electromyography (EMG). EMG electrodes were attached to the abductor digiti minimi (ADM) muscle of the right hand during stimulation of the left primary motor cortex, allowing for the determination of optimal ADM muscle activation. The RMT was determined at each session and was defined as the minimal stimulation intensity required to elicit a motor-evoked response of 50 μ V peak-to-peak amplitude in at least 5 out of 10 consecutive trials of motor cortex stimulation in the contralateral ADM muscle. The rTMS was well tolerated with no lasting side effects and only minor transient fatigue. TMS treatment is known to cause fatigue and minor irritation at the site, both of which resolve within hours.

OUTCOME AND FOLLOW-UP

Data were collected with multiple outcome measures, including dizziness symptom severity, dizziness symptom frequency, cognition, anxiety, depression, post-traumatic stress disorder and quality of life, at 2 weeks pretreatment, immediately following treatment, 1 month post treatment and 3 months post treatment. Pretreatment dizziness severity was reduced from 6.14 to 5.00 at 1 month post treatment and further reduced to 3.00 at 3 months on a 10-point Likert scale following rTMS completion. Symptom frequency (episodes of dizziness per week) was also reduced from 58.5 episodes/week prior to treatment, to 48 episodes/week at 1 month post treatment to 21 episodes/week at 3 months post treatment. The Dizziness Handicap Inventory (DHI) was used to assess the impact of dizziness on quality of life, with a disability cut-off point at 29/100 possible points.¹⁹ The patient's DHI was 40/100 prior to rTMS treatment initiation and was reduced to 26/100 at 3 months post treatment. The minimally important change for the DHI has been identified by Tamber *et al*¹⁹ to be 11 points, signifying this to be a significant reduction in dizziness disability. Quality of life improved slightly from 88/100 to 93/100 at 1 month post treatment, and to 95/100 at 3 months post treatment, using the Quality of Life after Brain Injury Questionnaire. All other outcome measures were nil at baseline or minimally changed.

DISCUSSION

Dizziness is a common problem following mTBL.¹⁰ Post-traumatic dizziness as a symptom of acute mTBI has been noted to abate earlier than other symptoms such as fatigue and headache.²⁰ However, in those patients with persistent post-traumatic dizziness-targeted therapies such as vestibular and vision therapy can be particularly helpful, especially those that persist beyond the first couple of weeks post injury.^{7,21} The patient described in the current case report, however, has relatively normal performances in all relevant vestibular and vision therapies with littleto-no effect.

Non-invasive brain stimulation techniques such as rTMS have become increasingly studied as tools for inducing short-term and long-term physiological effects in the brain.²² While the

Novel treatment (new drug/intervention; established drug/procedure in new situation)

true mechanism is still currently unknown, theoretically, given the neurophysiological effects of TMS, this technique may: (1) decrease cortical hyperexcitability following acute mTBI; (2) modulate long-term synaptic plasticity and moderate maladaptive consequences of mTBI; and (3) facilitate cortical reorganisation and consolidation of learning in specific neural networks when combined with physical and behavioural therapy.²² While single pulse TMS causes transient faciliatory or inhibitory effects lasting up to 10 min, repetitive stimulation is crucial for longlasting therapeutic effects thought to be due to neuroplastic changes.²³ Since cortical projections of the vestibular system are widespread and interconnected with cognitive and affective networks, neuromodulation using rTMS could greatly influence motion perception and postural control.²⁴

PPCS include somatic concerns such as headache, fatigue, anxiety, depressive symptoms, irritability, dizziness and cognitive deficits^{25 26} and it has been suggested that these comorbidities are interrelated.²⁷ Thus, Koski *et al*²⁵ have hypothesised that rTMS over the DLPFC, which is an effective treatment for symptoms of major depressive disorder, may have utility in alleviating PPCS. In a study using a near-identical treatment protocol to the one described in this case, Koski *et al* showed a significant reduction in PPCS following 20 rTMS sessions in patients with mTBI with symptoms persisting for greater than 3 months.²⁵

rTMS has been used as a treatment for other causes of dizziness. A double-blind sham-controlled study of eight righthanded women with a history of classic motion-triggered Mal de Debarquement Syndrome used 10 Hz rTMS stimulation of the left DLPFC and found a significant improvement in dizziness, mood and anxiety symptoms.²⁴ This study also used the DHI as a primary outcome measure for disability secondary to dizziness. Average baseline DHI scores were 45/100, and a reduction of approximately 10 points was seen in patients who received true rTMS, compared with sham, at 4 weeks post treatment similar to the results in this case report.

While rTMS has been studied more extensively in the treatment of depression,²⁸ ²⁹ stroke rehabilitation³⁰ ³¹ and even tinnitus,³² ³³ more work is needed to study the potential therapeutic effects in larger populations of patients who suffer from

Patient's perspective

I got to a point following my injury where I was looking for anything to help with my symptoms, and to a point where I felt that I had nothing to lose. I was willing to try anything. With regards to the treatment, there was some notable benefit. I would not consider it to be time-consuming and it was certainly not invasive. Generally, I would conclude that there were positive benefits, and I'm definitely less symptomatic now following the treatment compared to prior. It seems the symptomatic episodes are more noticeable now, only because they occur so infrequently. It's not even something I'm really thinking about anymore. Occasionally I'm reminded that I still have a brain injury, but for the most part (other than climbing ladders or participating in similar activities) I haven't imposed restrictions on anything that I do anymore. I've been thinking of riding my bike around the block for the first time in at least 4 years. In terms of normal day-to-day living, I no longer dwell on the symptoms. If you look at the timing, one would suspect that the result must be correlated to the treatment. I don't think anyone would object to this type of treatment, given how non-invasive it is. I'd certainly recommend the treatment to anyone.

PPCS, particularly chronic post-traumatic dizziness. With a cost of \$C300 per session, a protocol of 10 rTMS sessions has a relatively low-cost burden compared with many conventional therapies. Here, we propose that rTMS was a safe, effective and cost-effective treatment option for a patient who experience persistent debilitating dizziness secondary to mTBI.

Learning points

- Repetitive transcranial magnetic stimulation (rTMS) was safely administered to a patient with persistent postconcussion syndrome (PPCS) and treatment refractory idiopathic post-traumatic dizziness.
- This case report suggests that rTMS may improve posttraumatic dizziness symptoms burden at 1 and 3 months post treatment, but larger randomised control studies are necessary.
- A protocol of 10 rTMS sessions shares a similar if not lower cost burden than each of the conventional therapies previously tried by this patient.
- This case report suggests that rTMS may clinically improve the impact of dizziness on quality of life based on the Dizziness Handicap Inventory in a patient with PPCS and idiopathic post-traumatic dizziness at 1 and 3 months post treatment, but larger randomised controls trials are necessary.
- The mechanism of action and duration of symptom relief remains unknown; therefore, studies focusing on pathophysiology and long-term follow-up would be beneficial.

Acknowledgements The authors would like to acknowledge the support of Adam Kirton, Ouri Monchi and Frank McMaster who lead the neurostimulation initiative at the University of Calgary, Calgary, Alberta, Canada. Their expertise, support and guidance were greatly appreciated. We would also like to thank Liu Shi Gan for her help with the rTMS set-up and implementation.

Contributors All authors contributed substantially to the concept of the project, data collection, treatment and follow-up of the patient. Specifically, EP was involved in data collection, data analysis and writing of the manuscript. JS was involved in design of the project, data collection, data analysis and reviewing the manuscript. LM aided in developing the project, data collection and data analysis. CTD oversaw the project and was involved in all aspects of the work.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Gardner RC, Yaffe K. Epidemiology of mild traumatic brain injury and neurodegenerative disease. *Mol Cell Neurosci* 2015;66:75–80.
- 2 Cassidy JD, Carroll LJ, Peloso PM, et al. Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med 2004:28–60.
- 3 Setnik L, Bazarian JJ. The characteristics of patients who do not seek medical treatment for traumatic brain injury. *Brain Inj* 2007;21:1–9.
- 4 Styrke J, Stålnacke BM, Sojka P, et al. Traumatic brain injuries in a well-defined population: epidemiological aspects and severity. J Neurotrauma 2007;24:1425–36.
- 5 Barlow KM, Crawford S, Stevenson A, et al. Epidemiology of postconcussion syndrome in pediatric mild traumatic brain injury. *Pediatrics* 2010;126:e374–e381.
- 6 Babcock L, Byczkowski T, Wade SL, et al. Predicting postconcussion syndrome after mild traumatic brain injury in children and adolescents who present to the emergency department. JAMA Pediatr 2013;167:156–61.
- 7 Fridinger S, Stephenson D. Post-concussion syndrome and neurologic complications. *Curr Pediatr Rep* 2018;6:1–8.
- 8 Ontario Neurotrauma Foundation. Guidelines for Concussion/Mild Traumatic Brain Injury and Persistent Symptoms: Second Edition: Ontario Neurotrauma Foundation,

Novel treatment (new drug/intervention; established drug/procedure in new situation)

2013. S.I. U6 - ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_ id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt% 3Akev%3Amtx%3Abook&rft.genre=book&rft.title=Guidelines+for+Concussion% 2FMild+Traumatic+Brain+Injury+and+Persistent+Symptoms&rft.date=2013-01-01&rft.pub=Ontario+Neurotrauma+Foundation&rft.externalDBID=QYQSW&rft. externalDocID=ssib016584546¶mdict=en-US U7.

- 9 Morgan CD, Zuckerman SL, Lee YM, et al. Predictors of postconcussion syndrome after sports-related concussion in young athletes: a matched case-control study. J Neurosurg Pediatr 2015;15:589–98.
- Corwin DJ, Wiebe DJ, Zonfrillo MR, et al. Vestibular deficits following youth concussion. J Pediatr 2015;166:1221–5.
- 11 Lau BC, Kontos AP, Collins MW, et al. Which on-field signs/symptoms predict protracted recovery from sport-related concussion among high school football players? Am J Sports Med 2011;39:2311–8.
- 12 Parnes LS, Agrawal SK, Atlas J. Diagnosis and management of benign paroxysmal positional vertigo (BPPV). CMAJ 2003;169:681–93.
- 13 Smith-Seemiller L, Fow NR, Kant R, et al. Presence of post-concussion syndrome symptoms in patients with chronic pain vs mild traumatic brain injury. Brain Inj 2003;17:199–206.
- 14 Kalita J, Laskar S, Bhoi SK, *et al*. Efficacy of single versus three sessions of high rate repetitive transcranial magnetic stimulation in chronic migraine and tension-type headache. *J Neurol* 2016;263:2238–46.
- 15 Misra UK, Kalita J, Bhoi SK. High frequency repetitive transcranial magnetic stimulation (rTMS) is effective in migraine prophylaxis: an open labeled study. *Neurol Res* 2012;34:547–51.
- 16 Misra UK, Kalita J, Bhoi SK. High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study. J Neurol 2013;260:2793–801.
- 17 Misra UK, Kalita J, Tripathi G, et al. Role of β endorphin in pain relief following high rate repetitive transcranial magnetic stimulation in migraine. Brain Stimul 2017;10:618–23.
- 18 Tripathi GM, Kalita J, Misra UK. Role of glutamate and its receptors in migraine with reference to amitriptyline and transcranial magnetic stimulation therapy. *Brain Res* 2018;1696:31–7.
- 19 Tamber AL, Wilhelmsen KT, Strand LI. Measurement properties of the dizziness handicap inventory by cross-sectional and longitudinal designs. *Health Qual Life Outcomes* 2009;7:101.

- 20 Eisenberg MA, Meehan WP, Mannix R. Duration and course of post-concussive symptoms. *Pediatrics* 2014;133:999–1006.
- 21 Vidal PG, Goodman AM, Colin A, et al. Rehabilitation strategies for prolonged recovery in pediatric and adolescent concussion. *Pediatr Ann* 2012;41:1–7.
- 22 Villamar MF, Santos Portilla A, Fregni F, et al. Noninvasive brain stimulation to modulate neuroplasticity in traumatic brain injury. *Neuromodulation* 2012;15:326–38.
- 23 Bortolomasi M, Minelli A, Fuggetta G, et al. Long-lasting effects of high frequency repetitive transcranial magnetic stimulation in major depressed patients. Psychiatry Res 2007;150:181–6.
- 24 Cha YH, Deblieck C, Wu AD. Double-blind sham-controlled crossover trial of repetitive transcranial magnetic stimulation for mal de debarquement syndrome. *Otol Neurotol* 2016;37:805–12.
- 25 Koski L, Kolivakis T, Yu C, et al. Noninvasive brain stimulation for persistent postconcussion symptoms in mild traumatic brain injury. J Neurotrauma 2015;32:38-44.
- 26 Bottari C, Dassa C, Rainville C, *et al*. A generalizability study of the instrumental activities of daily living profile. *Arch Phys Med Rehabil* 2010;91:734–42.
- 27 Deb S, Lyons I, Koutzoukis C. Neuropsychiatric sequelae one year after a minor head injury. J Neurol Neurosurg Psychiatry 1998;65:899–902.
- 28 Gaynes BN, Lloyd SW, Lux L, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry 2014;75:477–89.
- 29 Daskalakis ZJ, Levinson AJ, Fitzgerald PB. Repetitive transcranial magnetic stimulation for major depressive disorder: a review. *Can J Psychiatry* 2008;53:A1–A2.
- 30 Boggio PS, Nunes A, Rigonatti SP, et al. Repeated sessions of noninvasive brain DC stimulation is associated with motor function improvement in stroke patients. *Restor Neurol Neurosci* 2007;25:123–9.
- 31 Mylius V, Zouari HG, Ayache SS, et al. Stroke rehabilitation using noninvasive cortical stimulation: aphasia. Expert Rev Neurother 2012;12:973–82.
- 32 Labar DR, Cortes M, Edwards D. Long-term repetitive transcranial magnetic stimulation therapy: new research questions arising from one tinnitus case? *BMJ Case Rep* 2014;2014:bcr2014207203.
- 33 Kleinjung T, Steffens T, Londero A, *et al*.n: Langguth B, Hajak G, Kleinjung T, Cacace A, Møller AR, . *Transcranial magnetic stimulation (TMS) for treatment of chronic tinnitus: clinical effect*. : Elsevier Prog Brain Res, 2007:166: 359–551.

Copyright 2018 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit http://group.bmj.com/group/rights-licensing/permissions.

BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- Submit as many cases as you like
- Enjoy fast sympathetic peer review and rapid publication of accepted articles
- Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow